CR11427A - 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa - Google Patents

2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa

Info

Publication number
CR11427A
CR11427A CR11427A CR11427A CR11427A CR 11427 A CR11427 A CR 11427A CR 11427 A CR11427 A CR 11427A CR 11427 A CR11427 A CR 11427A CR 11427 A CR11427 A CR 11427A
Authority
CR
Costa Rica
Prior art keywords
deoxitetrahydrouridins
desaminase
citidine
fluoro
inhibitors
Prior art date
Application number
CR11427A
Other languages
English (en)
Inventor
Gregory S Hamilton
Takashi Tsukamoto
Dana V Ferraris
Bridget Duvall
Rena Lapidus
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Inc filed Critical Eisai Inc
Publication of CR11427A publication Critical patent/CR11427A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion provee determinados compuestos derivados de tetrahidrouridina, composiciones farmaceuticas y kits que comprenden tales compuestos y metodos de preparacion y uso de tales compuestos.
CR11427A 2007-10-16 2010-05-12 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa CR11427A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98039707P 2007-10-16 2007-10-16

Publications (1)

Publication Number Publication Date
CR11427A true CR11427A (es) 2010-08-16

Family

ID=40251685

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11427A CR11427A (es) 2007-10-16 2010-05-12 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa

Country Status (39)

Country Link
US (4) US8268800B2 (es)
EP (2) EP2207786B1 (es)
JP (2) JP5496899B2 (es)
KR (1) KR101543049B1 (es)
CN (1) CN101827856B (es)
AT (1) ATE548374T1 (es)
BR (1) BRPI0818672B8 (es)
CA (1) CA2702274C (es)
CO (1) CO6270330A2 (es)
CR (1) CR11427A (es)
CY (3) CY1112781T1 (es)
DK (1) DK2207786T3 (es)
EA (1) EA018757B1 (es)
EC (1) ECSP10010095A (es)
ES (2) ES2616566T3 (es)
FI (2) FIC20230039I1 (es)
FR (2) FR23C1052I1 (es)
GT (1) GT201000088A (es)
HK (1) HK1146410A1 (es)
HR (1) HRP20120419T1 (es)
HU (2) HUS2300045I1 (es)
IL (1) IL204732A (es)
JO (1) JO2778B1 (es)
ME (1) ME00997B (es)
MX (1) MX2010004109A (es)
MY (1) MY147970A (es)
NI (1) NI201000055A (es)
NL (1) NL301256I2 (es)
NO (2) NO2023047I1 (es)
NZ (1) NZ584229A (es)
PL (1) PL2207786T3 (es)
PT (1) PT2207786E (es)
RS (1) RS52323B (es)
SA (1) SA08290661B1 (es)
SI (1) SI2207786T1 (es)
TW (1) TWI445539B (es)
UA (1) UA99476C2 (es)
WO (1) WO2009052287A1 (es)
ZA (1) ZA201002178B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
PL2299984T3 (pl) 2008-05-15 2019-07-31 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
PA8855801A1 (es) 2008-12-23 2010-07-27 Sintesis de nucleosidos de purina
TWI477508B (zh) * 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
AU2010234562B2 (en) * 2009-04-06 2016-05-12 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
UY32546A (es) 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
BR112014006324B8 (pt) 2011-09-16 2019-02-12 Gilead Pharmassett Llc composição e seu uso para o tratamento de hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN104144682A (zh) 2013-01-31 2014-11-12 吉利德法莫赛特有限责任公司 两个抗病毒化合物的联用制剂
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
JP6427567B2 (ja) 2013-10-29 2018-11-21 大塚製薬株式会社 ２’−デオキシ−２’，２’−ジフルオロテトラヒドロウリジンへの合成経路
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US10034872B2 (en) 2014-08-22 2018-07-31 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
EP3383406B1 (en) 2015-12-03 2021-10-20 Epidestiny, Inc. Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof
WO2017158396A1 (en) * 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
EP3746134A1 (en) 2018-02-02 2020-12-09 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
EP3868774A4 (en) * 2018-10-19 2023-05-10 Interoligo Corporation MODIFIED NUCLEIC ACID WITH IMPROVED TREATMENT EFFICIENCY AND ANTI-CANCER PHARMACEUTICAL COMPOSITION THEREOF
WO2020080912A1 (ko) * 2018-10-19 2020-04-23 인터올리고 주식회사 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물
US20220411457A1 (en) * 2019-10-08 2022-12-29 Otsuka Pharmaceutical Co., Ltd. 2'-deoxy-2',2'-difluorotetrahydrouridines with high purity and methods of making the same
IL294288A (en) * 2020-02-25 2022-08-01 Otsuka Pharma Co Ltd Solid oral dosage forms in combination with decitabine and cadazuridine
CA3211943A1 (en) * 2021-03-26 2022-09-29 Yogen Saunthararajah Treatment of rna virus infection with a cytidine deaminase inhibitor
US20240279266A1 (en) * 2021-05-29 2024-08-22 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
WO2023069529A1 (en) 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
WO2023076332A1 (en) * 2021-11-01 2023-05-04 St. John's University Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
TW202410893A (zh) 2022-08-31 2024-03-16 日商大塚製藥股份有限公司 用於治療t細胞淋巴瘤之結合治療

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4275057A (en) * 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
WO1985001871A1 (en) 1983-10-26 1985-05-09 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
WO1992018617A1 (en) 1991-04-23 1992-10-29 Oglevee, Ltd. In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) * 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
DE69403588T2 (de) * 1993-02-23 1998-01-22 Hope City 4-ethoxy-5-fluor-2'-deoxyuridine
AU6081294A (en) * 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
WO1996026743A1 (en) * 1995-03-01 1996-09-06 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) * 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
ATE339960T1 (de) 1999-03-01 2006-10-15 Halogenetics Inc Verwendung von zusammensetzungen enthaltend cldc als strahlungssensibilisatoren in der behandlung von neoplastischen erkrankungen
US6933287B1 (en) * 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
NZ517437A (en) 1999-08-26 2004-02-27 Omega Critical Care Ltd Improvements relating to catheter positioning
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
US7125983B2 (en) * 2000-11-29 2006-10-24 Mitsui Chemicals, Inc. L-nucleic acid derivatives and process for the synthesis thereof
US7141576B2 (en) * 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
EP1387850A2 (en) 2001-05-18 2004-02-11 Rakesh Kumar Antiviral nucleosides
US8207142B2 (en) * 2001-07-31 2012-06-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitor of DNA methylation
MXPA04007876A (es) 2002-02-14 2005-06-20 Pharmasset Ltd Analogos de nucleosido fluorado modificados.
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US7772197B2 (en) 2002-09-24 2010-08-10 1,3,5-Triazines for Treatment of Viral Diseases 1,3,5-triazines for treatment of viral diseases
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
WO2005115410A2 (en) * 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
CN101076536A (zh) 2004-07-30 2007-11-21 药华医药股份有限公司 β－核苷的立体选择性合成
WO2006063105A1 (en) 2004-12-08 2006-06-15 Sicor Inc. Difluoronucleosides and process for preparation thereof
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
AU2010234562B2 (en) * 2009-04-06 2016-05-12 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
TWI477508B (zh) * 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
UY32546A (es) * 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer

Also Published As

Publication number Publication date
FIC20230039I1 (fi) 2023-12-22
WO2009052287A1 (en) 2009-04-23
BRPI0818672A2 (pt) 2015-04-14
MY147970A (en) 2013-02-28
ECSP10010095A (es) 2010-07-30
PT2207786E (pt) 2012-05-28
US8951987B2 (en) 2015-02-10
CA2702274C (en) 2015-12-29
KR20100091978A (ko) 2010-08-19
AU2008312435A1 (en) 2009-04-23
CA2702274A1 (en) 2009-04-23
BRPI0818672B8 (pt) 2021-05-25
TW200924786A (en) 2009-06-16
JP2014177455A (ja) 2014-09-25
ME00997B (me) 2012-10-20
CY2023029I1 (el) 2024-02-16
EP2207786B1 (en) 2012-03-07
JP2011500713A (ja) 2011-01-06
ES2616566T3 (es) 2017-06-13
US8268800B2 (en) 2012-09-18
BRPI0818672B1 (pt) 2020-10-20
RS52323B (en) 2012-12-31
CY2023028I1 (el) 2024-02-16
US8618075B2 (en) 2013-12-31
US20140186335A1 (en) 2014-07-03
HK1146410A1 (en) 2011-06-03
CN101827856B (zh) 2013-02-06
SA08290661B1 (ar) 2012-06-10
EA201000642A1 (ru) 2010-10-29
ZA201002178B (en) 2011-05-25
UA99476C2 (en) 2012-08-27
GT201000088A (es) 2012-03-13
NI201000055A (es) 2010-08-13
US20150210730A1 (en) 2015-07-30
HUS2300044I1 (hu) 2024-01-28
EA018757B1 (ru) 2013-10-30
SI2207786T1 (sl) 2012-10-30
EP2207786A1 (en) 2010-07-21
JP5859588B2 (ja) 2016-02-10
CN101827856A (zh) 2010-09-08
EP2447272B1 (en) 2017-02-01
NL301256I2 (nl) 2024-01-11
US20120289475A1 (en) 2012-11-15
IL204732A (en) 2013-07-31
US20090137521A1 (en) 2009-05-28
PL2207786T3 (pl) 2012-09-28
KR101543049B1 (ko) 2015-08-07
DK2207786T3 (da) 2012-06-18
NO2023047I1 (no) 2023-12-21
ES2384011T3 (es) 2012-06-28
JP5496899B2 (ja) 2014-05-21
TWI445539B (zh) 2014-07-21
NO2023048I1 (en) 2023-12-21
IL204732A0 (en) 2010-11-30
AU2008312435A8 (en) 2014-07-24
US9567363B2 (en) 2017-02-14
CO6270330A2 (es) 2011-04-20
CY1112781T1 (el) 2016-02-10
HRP20120419T1 (hr) 2012-07-31
AU2008312435B2 (en) 2014-04-17
NZ584229A (en) 2012-06-29
ATE548374T1 (de) 2012-03-15
JO2778B1 (en) 2014-03-15
FR23C1051I1 (fr) 2024-01-26
FIC20230040I1 (fi) 2023-12-22
NL301256I1 (es) 2024-01-03
EP2447272A1 (en) 2012-05-02
HUS2300045I1 (hu) 2024-01-28
FR23C1052I1 (fr) 2024-01-26
MX2010004109A (es) 2010-08-10

Similar Documents

Publication Publication Date Title
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
ECSP10010129A (es) Inhibidores de quinasas símil polo
PA8667201A1 (es) Nuevos compuestos farmaceuticos
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
ECSP12011855A (es) COMPUESTOS DE pIrrolo[2,3-d]pIrimidinA
ECSP10010246A (es) Inhibidores de beta-lactamasa
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
PA8842101A1 (es) Heteroarilos sustituidos
BR112013004341A2 (pt) composições pesticidas
CO6290760A2 (es) Derivados de alcoholes de 1 fenil-2-piridinilalquilo como inbidores de la fosfodiesterasa
DOP2006000051A (es) Inhibidores de vegf-r2 y métodos
NO20084334L (no) Farmasoytiske sammensetninger
CR20110135A (es) INHIBIDORES DE cMET
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
CR9786A (es) Compuestos de bencimidazol-tiofeno
UY32077A (es) Inhibidores de quinasa tipo polo
SV2009003429A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen